Astrazeneca (NYSE:AZN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday,MarketScreener reports.
Several other equities analysts have also recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, Barclays raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.
Astrazeneca Stock Down 1.3%
Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. As a group, research analysts expect that Astrazeneca will post 10.26 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC lifted its stake in shares of Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares during the period. AQR Capital Management LLC raised its stake in Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares during the last quarter. Amundi lifted its position in Astrazeneca by 54.4% during the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after acquiring an additional 3,618 shares during the period. Jump Financial LLC lifted its position in Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. grew its stake in Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after purchasing an additional 559 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Read More
- Five stocks we like better than Astrazeneca
- A New Focus for GoPro: Is a Takeover in the Frame?
- Palantir’s Critics Are “Right”—But They’re Also Still Wrong
- Chime Finally Turns Profitable—But Risks Remain
- eVTOL Investing: Ditch the Taxi, Buy the Blueprint
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
